KRAS and colorectal carcinoma: Although KRAS mutation status has been found in studies to be a biomarker for CRC response to EGFR-targeted therapy, however, a global phase III ASPECCT study detected RAS ctDNA mutations in panitumumab-treated mCRC patients, and emergent ctDNA RAS mutations were not associated with poor prognosis in panitumumab-treated patients [93].